Skip to Main Content

Paper Details

SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.
Lancet Diabetes Endocrinol
59
2019
HbA1c, SGLT2, Sodium, Sodium-glucose co-transporter-2, canagliflozin, dapagliflozin, diabetic ketoacidosis, empagliflozin, glucose, insulin, ketoacidosis, patient, patients, sotagliflozin, type 1 diabetes, type 2 diabetes
Author NameAffiliation
Kristina I RotherNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health
Amber L BeitelsheesUniversity of Maryland School of Medicine
  • 1 - 2

Datasets

Release 1.2